Literature DB >> 24462867

miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression.

Yong Gao1, Ling-hui Luo2, Shuai Li3, Cao Yang3.   

Abstract

MicroRNAs (miRNAs) play essential roles in cancer development and progression. Here, we investigated the role of miR-17 in the progression and metastasis of osteosarcoma (OS). miR-17 was frequently increased in OS tissues and cell lines. Inhibition of miR-17 in OS cell lines substantially suppressed cell proliferation, migration, and invasion. Phosphatase and tensin homolog (PTEN) was identified as a target of miR-17, and ectopic expression of miR-17 inhibited PTEN by direct binding to its 3'-untranslated region (3'-UTR). Expression of miR-17 was negatively correlated with PTEN in OS tissues. Together, these findings indicate that miR-17 acts as an oncogenic miRNA and may contribute to the progression and metastasis of OS, suggesting miR-17 as a potential novel diagnostic and therapeutic target of OS.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Invasion; Migration; Osteosarcoma; PTEN; Proliferation; miR-17

Mesh:

Substances:

Year:  2014        PMID: 24462867     DOI: 10.1016/j.bbrc.2014.01.061

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

1.  MicroRNA-196a overexpression promotes cell proliferation and inhibits cell apoptosis through PTEN/Akt/FOXO1 pathway.

Authors:  Yong Shang; Li-Qing Wang; Quan-Yi Guo; Tu-Long Shi
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

3.  Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN.

Authors:  Xiang Xia; Kundong Zhang; Guangtao Luo; Gang Cen; Jun Cao; Kejian Huang; Zhengjun Qiu
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

4.  miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.

Authors:  Shuguang Zhou; Bing Wang; Jun Hu; Yucheng Zhou; Mengzhen Jiang; Mingyu Wu; Liming Qin; Xuming Yang
Journal:  Tumour Biol       Date:  2016-01-13

Review 5.  Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.

Authors:  Hui Jun Lim; Philip Crowe; Jia-Lin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-22       Impact factor: 4.553

Review 6.  Review of microRNA in osteosarcoma and chondrosarcoma.

Authors:  Le Chang; Swati Shrestha; Greg LaChaud; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-04-26       Impact factor: 3.064

7.  A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis.

Authors:  Branden S Moriarity; George M Otto; Eric P Rahrmann; Susan K Rathe; Natalie K Wolf; Madison T Weg; Luke A Manlove; Rebecca S LaRue; Nuri A Temiz; Sam D Molyneux; Kwangmin Choi; Kevin J Holly; Aaron L Sarver; Milcah C Scott; Colleen L Forster; Jaime F Modiano; Chand Khanna; Stephen M Hewitt; Rama Khokha; Yi Yang; Richard Gorlick; Michael A Dyer; David A Largaespada
Journal:  Nat Genet       Date:  2015-05-11       Impact factor: 38.330

8.  miR-92b regulates glioma cells proliferation, migration, invasion, and apoptosis via PTEN/Akt signaling pathway.

Authors:  Hang Song; Yao Zhang; Na Liu; Chao Wan; Dongdong Zhang; Sheng Zhao; Yan Kong; Liudi Yuan
Journal:  J Physiol Biochem       Date:  2016-02-18       Impact factor: 4.158

9.  MicroRNA-26b inhibits metastasis of osteosarcoma via targeting CTGF and Smad1.

Authors:  Guoqing Duan; Chunfeng Ren; Yuanmin Zhang; Shiqing Feng
Journal:  Tumour Biol       Date:  2015-03-12

10.  MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1.

Authors:  Enqi Li; Jinli Zhang; Tianxiang Yuan; Baotong Ma
Journal:  Tumour Biol       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.